Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

2005 - The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome


08 Oct 2016


Gynaecological cancers


Gwénaël Ferron


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


G. Ferron1, G. De Rauglaudre2, I.L. Ray-Coquard3, A. Lesoin4, F. Joly5, A. Lortholary6, N. Raban7, J. Peron8, E. Malaurie-Agostini9, S. Gouy10, M. Kaminsky11, J. Meunier12, J. Alexandre13, D. Berton-Rigaud14, F. Coussy15, L. Favier16, L. Venat-Bouvet17, F. Marmion18, P. Combe19, E. Pujade-Lauraine20

Author affiliations

  • 1 Département De Chirurgie Oncologique, Institut Claudius Régaud, 31059 - Toulouse/FR
  • 2 Cancérologie Clinique, Institut Ste Catherine, Avignon/FR
  • 3 Département D'oncologie Médicale Adulte, Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Département De Gynécologie, Centre Oscar Lambret, Lille/FR
  • 5 Oncologie, Centre Francois Baclesse, Caen/FR
  • 6 Oncologie, Centre Catherine de Sienne, Nantes/FR
  • 7 Service D'oncologie, Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie, Poitiers/FR
  • 8 Oncologie Médicale - Pavillon 1f, Centre Hospitalier Lyon Sud, Pierre Bénite/FR
  • 9 Oncologie - Radiothérapie, CH Intercommunal de Créteil, Créteil/FR
  • 10 Service De Chirurgie Générale, Gustave Roussy, Villejuif/FR
  • 11 Oncologie Médicale, ICL Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy/FR
  • 12 Service Oncologie Médicale, Centre Hospitalier Régional d'Orléans, Orleans/FR
  • 13 Unité D'oncologie Médicale, Hôpital Cochin, Paris/FR
  • 14 Oncologie, ICO Centre René Gauducheau, Saint-Herblain/FR
  • 15 Oncologie, Hôpital René Huguenin, Saint-Cloud/FR
  • 16 Oncologie Médicale, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 17 Oncologie, CHU Limoges - Hopital Dupuytren, Limoges/FR
  • 18 Recherche Clinique, Arcagy-Gineco, Paris/FR
  • 19 Oncologie, Hopital European George Pompidou, Paris/FR
  • 20 Cancer De La Femme Et Recherche Clinique, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Paris/FR


Abstract 2005


Improving NACT response rate in pts with OC could lead to increased complete resection rate (CC0) at IDS and better survival. Bevacizumab has been shown to increase response rate to chemotherapy both in first-line (ICON7) and in relapse (OCEANS and AURELIA). Due to concerns about bevacizumab impact on IDS wound healing, the safety and efficacy of nintedanib, an orally available anti-VEGF/PDGFR/FGFR tyrosine kinase inhibitor with a short half-life was explored in the neo-adjuvant setting.


All patients underwent laparoscopy and their disease was considered as unresectable (impossibility to achieve CC0 at primary surgery). Eligible patients were randomized (2:1) to receive 3 cycles of NACT before IDS and 3 cycles of chemotherapy after IDS with carboplatin + paclitaxel and nintedanib or placebo (at cycle 1&2, 5&6 and at maintenance therapy as single agent during 2 years). The aim of IDS was to achieve CC0. Surgical complications were scored according to Clavien Dindo classification.


A total of 188 patients were included and 121 (64%) patients underwent IDS (49 in placebo arm and 72 in experimental arm). Pts characteristics are well balanced between both arms. No significant difference was observed between the placebo and the nintedanib arm in terms of operating procedure duration (360 vs 330 minutes) and per-operative (18 vs 13%) complications. Bleeding (2 vs 9% of the pts), blood losses (500 vs 675 ml), and transfusion rate (12 vs 26% of the pts) were slightly less frequent in the placebo arm. Around half of the patients experienced at least one postoperative complication: 53% versus 47% in the placebo and nintedanib arm respectively. They were mostly of grade I-II (86% grade I-II, 14% grade III-IVa) with no significant difference between the two arms in type and grade of postoperative complications.


Compare to placebo, the addition of the anti-VEGF nintedanib to neo-adjuvant chemotherapy did not significantly increase the rate of per-operative and post-operative complications of the interval debulking surgery.

Clinical trial identification


Legal entity responsible for the study



Boehringer Ingelheim


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings